Cartoon – Lack of Flexibility Problem

Dilbert on adaptive management

What “mild” really means when it comes to Omicron

https://www.axios.com/what-mild-really-means-when-it-comes-to-omicron-f808e5ba-5655-4ac5-b057-4afe3b0aa860.html?fbclid=IwAR27eTD0HrjsF_XiS_USEVn9MxermNoLWJNhU10AeIFQV_y59C7Fl3ok9RM

Illustration of a coronavirus cell in curly quotes.

The Omicron variant doesn’t cause as much severe illness as other variants have, but its “mild” symptoms can still be pretty unpleasant.

The big picture: The way health care professionals and doctors differentiate between “mild” and “severe” illness may not align with a layperson’s understanding of those terms.

“To a health care professional, ‘mild’ means you’re not getting hospitalized,” said Megan Ranney, academic dean at the Brown University School of Public Health.

  • But, she said: “Omicron symptoms can range from absolutely no symptoms to a really mild cold to something where you are in bed with shakes and chills, and have a horrible cough and are fatigued and headachy for weeks. Those are all ‘mild.'”
  • A “severe,” illness means you’d likely have symptoms such as very low oxygen levels, kidney damage and heart impairment, she said.

What we’re watching: Omicron is causing a lot less severe illness than previous variants, but a “mild” case can still require about a week away from work, especially in front-line jobs.

  • And because so many people have gotten infected in such a short time, it’s leaving schools, airlines, and other businesses — including, critically, hospitals — with large numbers of workers out sick simultaneously, The Atlantic reported.
  • Then there’s the matter of long COVID. A study published Thursday in Nature Immunology found ongoing, sustained inflammatory responses following even mild-to-moderate COVID-19 cases.

What they’re saying: “It’s going to be a messy few weeks. I don’t think there’s any way around it,” said Joseph Allen, a professor of public health at Harvard, per The Atlantic.

Consumer confidence unshaken by Omicron—at least so far

https://mailchi.mp/0b6c9295412a/the-weekly-gist-january-7-2022?e=d1e747d2d8

While Omicron’s rapid spread is causing COVID hospitalizations to surge once again, the impact on consumer confidence may be different this time around. Drawing on the most recent data from analytics firm Strata Decision Technology, the graphic above shows how hospital volumes have fluctuated throughout the pandemic. Hospital volumes mostly returned to pre-COVID levels early last summer, until the Delta surge caused patients to begin avoiding care across all settings once again. 

It remains to be seen if the forty percent of consumers who said they were less likely to seek non-emergency care during the Delta surge feel similarly about the Omicron spike. So far, consumer sentiment seems to be holding steady at last summer’s levels, though we’re still a few weeks away from Omicron’s expected peak. 

As the pandemic enters its third year, it’s also likely that consumers who have been delaying care will simply be unwilling or unable to hold off any longer. But even if Omicron doesn’t dissuade consumers from seeking non-COVID care, health systems will be hard pressed to accommodate both COVID and non-COVID care amid worrisome staffing shortages. 

Elizabeth Holmes found guilty of defrauding investors

https://mailchi.mp/0b6c9295412a/the-weekly-gist-january-7-2022?e=d1e747d2d8

  1. A San Jose jury convicted Theranos founder Elizabeth Holmes on four counts of fraud, deciding that she lied to investors while raising more than $700M in funds for the company. Holmes was found not guilty on four other counts relating to defrauding patients, though Theranos ended up voiding tens of thousands of erroneous test results. Each conviction carries a maximum twenty-year sentence, although Holmes is widely expected to appeal.

The Gist: It’s rare that tech executives are convicted of fraud. Investors, including many health systems, have been flooding healthcare startups with large sums of cash in hopes of big returns. But the Theranos debacle is a reminder that Silicon Valley’s “fake it till you make it culture” is not always the best fit for healthcare. Providers must continue to hold new medical technologies to high standards, regardless of how much promise they hold to “revolutionize” aspects of patient care.